Cargando…

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma

Detalles Bibliográficos
Autores principales:	Reuben, Alexandre, Cooper, Zachary A, Amaria, Rodabe N, Forget, Marie A, Haymaker, Cara, Bernatchez, Chantale, Chen, Pei-ling, Tetzlaff, Michael T, Chin, Lynda, Dwyer, Karen C, Wargo, Jennifer A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292414/ http://dx.doi.org/10.1186/2051-1426-2-S3-P200

Ejemplares similares

TIL therapy and anti-CTLA4: can they co-exist?
por: Forget, Marie-Andrée, et al.
Publicado: (2019)

Molecular and immune heterogeneity in synchronous melanoma metastases
por: Reuben, Alexandre, et al.
Publicado: (2015)

Update on use of aldesleukin for treatment of high-risk metastatic melanoma
por: Amaria, Rodabe N, et al.
Publicado: (2015)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study
por: Qin, Yong, et al.
Publicado: (2017)

You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes
por: Haymaker, Cara, et al.
Publicado: (2015)

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015)

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
por: Reuben, Alexandre, et al.
Publicado: (2017)

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
por: Pelster, Meredith S., et al.
Publicado: (2019)

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer
por: Sakellariou-Thompson, Donastas, et al.
Publicado: (2015)

Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity
por: Malu, Shruti, et al.
Publicado: (2013)

PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint
por: Haymaker, Cara, et al.
Publicado: (2012)

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
por: Cooper, Zachary A., et al.
Publicado: (2016)

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes
por: Forget, Marie-Andrée, et al.
Publicado: (2017)

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
por: McKenzie, Jodi A, et al.
Publicado: (2017)

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties
por: Haymaker, Cara L, et al.
Publicado: (2015)

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients
por: Martinez-Paniagua, Melisa, et al.
Publicado: (2015)

A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2016)

Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2017)

Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients
por: Tetzlaff, Michael T., et al.
Publicado: (2018)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity
por: Punt, Simone, et al.
Publicado: (2020)

The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity
por: Forget, Marie-Andrée, et al.
Publicado: (2015)

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control
por: Ritthipichai, Krit, et al.
Publicado: (2015)

Uncovering a novel function of BTLA on tumor-infiltrating CD8+ T cells
por: Haymaker, Cara, et al.
Publicado: (2013)

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
por: Parra, Edwin R., et al.
Publicado: (2017)

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jie Qing, et al.
Publicado: (2013)

Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis
por: Ito, Takamichi, et al.
Publicado: (2019)

Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma
por: Menzies, Alexander M., et al.
Publicado: (2014)

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report
por: Uemura, Marc, et al.
Publicado: (2016)

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases
por: PELLEGRINI, Cristina, et al.
Publicado: (2020)

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
por: Sloane, Robert A. Szczepaniak, et al.
Publicado: (2021)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
por: Im, Jin S., et al.
Publicado: (2016)

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts
por: Kemper, Kristel, et al.
Publicado: (2015)

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
por: Glitza, Isabella C, et al.
Publicado: (2018)

Phylogenetic Quantification of Intra-tumour Heterogeneity
por: Schwarz, Roland F., et al.
Publicado: (2014)

Breast cancer intra-tumor heterogeneity
por: Martelotto, Luciano G, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k33hdibusffmj2is7hvikv2uir